LHPP suppresses proliferation, migration, and invasion in hepatocellular carcinoma and pancreatic cancer by inhibiting EGFR signaling pathway.

Abstract

Phospholysine phosphohistidine inorganic pyrophosphate phosphatase (LHPP) has been reported to be a new tumor suppressor with a significant inhibitory effect in various cancers. Although LHPP has been repeatedly shown to inhibit the progression of various tumors by inhibiting the phosphorylation of AKT, up to now, the studies on the function and mechanism of LHPP in tumors are insufficient. In this study, LHPP expression was found to be downregulated in both hepatocellular carcinoma (HCC) and pancreatic cancer (PC). Here, we found that LHPP could bind to epidermal growth factor receptor (EGFR) and inhibit its phosphorylation, which thereby inhibited the activation of EGFR downstream pathways ERK, AKT, and STAT3, and then weakening the ability to proliferate, invade, and migrate in HCC and PC. This paper showed a new physiological function of LHPP in inhibiting phosphorylation of EGFR and its potential anti-tumor mechanism and indicated that LHPP was a potential therapeutic target for HCC and PC.

• Authors: Haitao Zhu, Chunzhuo Song, Junjun Li, Qianfan Liu, Meng Liu, Liyue Fu
• Journal: Medical oncology (Northwood, London, England) (Med Oncol) Vol. 40 Issue 9 Pg. 257 (Jul 31 2023) ISSN: 1559-131X [Electronic] United States
• PMID: 37522936 (Publication Type: Journal Article)
• Copyright: © 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Chemical References

• Proto-Oncogene Proteins c-akt
• ErbB Receptors
• EGFR protein, human

Topics

• Humans
• Carcinoma, Hepatocellular (pathology)
• Proto-Oncogene Proteins c-akt (metabolism)
• Cell Proliferation
• Liver Neoplasms (pathology)
• Cell Line, Tumor
• Signal Transduction
• ErbB Receptors (metabolism)
• Pancreatic Neoplasms
• Cell Movement